Welcome to Paid Research Studies.


Browse Locations ... United States» ... West Virginia» ... Charleston






  • Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

    Condition:   Pneumonia, Bacterial
    Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
    Sponsors:   Bayer;   Bayer;   Nektar Therapeutics
    Recruiting - verified May 2013
  • Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Fulvestrant;   Drug: Everolimus;   Drug: Placebo (for Everolimus)
    Sponsors:   PrECOG, LLC.;   PrECOG, LLC.;   Novartis
    Recruiting - verified June 2013
  • Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

    Conditions:   Type 2 Diabetes Mellitus;   Cardiovascular Disease
    Intervention:   Drug: Saxagliptin
    Sponsors:   Duke University;   Duke University
    Recruiting - verified June 2013
  • Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump

    Condition:   Management of Chronic Pain
    Interventions:   Drug: Hydromorphone Hydrochloride;   Drug: Hydromorphone Hydrochloride
    Sponsors:   CNS Therapeutics;   CNS Therapeutics;   Pacific-Link Consulting LLC
    Recruiting - verified June 2013
  • Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

    Conditions:   Renal Artery Stenosis;   Hypertension, Renovascular
    Intervention:   Device: iCAST™ Rx Stent System
    Sponsors:   Atrium Medical Corporation;   Atrium Medical Corporation
    Recruiting - verified May 2013
  • Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab [Avastin];   Drug: Placebo
    Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
    Recruiting - verified June 2013
  • Afatinib Expanded Access Program

    Condition:   Carcinoma, Non-Small-Cell Lung
    Intervention:   Drug: afatinib
    Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
    Available - verified June 2013
  • A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

    Condition:   Acute Kidney Injury
    Interventions:   Biological: AC607;   Biological: Vehicle Only
    Sponsors:   AlloCure Inc.;   AlloCure Inc.
    Recruiting - verified June 2013
  • Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

    Conditions:   Fungal Infection;   Leukemia;   Neutropenia
    Interventions:   Drug: caspofungin acetate;   Drug: fluconazole
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2013
  • Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

    Conditions:   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

    Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Other: clinical observation;   Drug: lenalidomide;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
    Recruiting - verified May 2013
  • Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

    Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
    Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

    Conditions:   Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
    Interventions:   Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Study of NNZ-2566 in Patients With Traumatic Brain Injury

    Condition:   Brain Injuries
    Intervention:   Drug: NNZ-2566
    Sponsors:   Neuren Pharmaceuticals Limited;   Neuren Pharmaceuticals Limited
    Recruiting - verified May 2013
  • Neuropsychological and Behavioral Testing in Young Patients With Cancer

    Conditions:   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

    Conditions:   Untreated Childhood Medulloblastoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Biological: filgrastim;   Drug: cisplatin;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

    Condition:   Kidney Cancer
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

    Conditions:   Brain Tumor;   Central Nervous System Tumor
    Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Study of Late-Occurring Complications in Childhood Cancer Survivors

    Conditions:   Cancer Survivor;   Cardiovascular Complications;   Hematopoietic/Lymphoid Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2013
Main Menu
Clinical Trial Locations
Clinical Trial Categories